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Introduction
Meningiomas constitute about 15% of all intracranial
tumors in adults. They are usually benign masses that
rarely invade the substance of the brain, thus potentially
allowing for curative surgery. Twenty percent are
anaplastic [1, 2]. Surgery is the basic treatment method,
however, it should be stressed that despite the progress in
microsurgery the total removal of meningioma is
impossible in some cases. External beam irradiation
would seem to be beneficial for aggressive meningiomas
and allows to inhibit or delay local recurrence [3-5].
The aim of this paper is to assess the value of
postoperative radiotherapy in adult meningioma patients.
Material and methods
The study population was referred to the Maria Sk∏odowska-
Curie Memorial Cancer Center in Kraków for radiation therapy
from neurosurgical centres. Between January 1975 and
December 1995, 76 patients with histologically confirmed
diagnosis of intracranial meningioma underwent postoperative
irradiation. The studied group consisted of 41 women and 35
men. The oldest patient was 66, the youngest 20 years of age.
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P u r p o s e.  To present our own experience in postoperative irradiation of adult patients with intracranial meningioma.
M a t e r i a l  a n d  m e t h o d s.  From January 1975 to December 1995, 76 patients with intracranial meningiomas received
postoperative irradiation. Conventional treatment techniques and standard doses 50-60 Gy (median dose 51 Gy) were
administered.
R e s u l t s.  Treatment tolerance was very good. The-10 year actuarial overall survival (AOS) in the whole group was 69%.
Patients with benign meningiomas (40 cases) had better prognosis in comparison to the patients with malignant variants of this
tumor. 10-year AOS were 77% and 50% respectively. This difference was statistically significant (p=0.0125). Age and
gender of patients, tumor location, and extent of surgery did not influence AOS
C o n c l u s i o n.  Fractionated radiation therapy appears to be an effective and well tolerated treatment in postoperative
management of adult patients with intracranial meningioma.
Wyniki pooperacyjnej radioterapii doros∏ych chorych na oponiaki Êródczaszkowe
C e l  p r a c y.  Przedstawienie doÊwiadczeƒ w∏asnych w pooperacyjnym napromienianiu doros∏ych chorych na oponiaki
Êródczaszkowe.
M a t e r i a ∏  i m e t o d a.  W okresie od stycznia 1975 roku do grudnia 1995 roku, w Klinice Radioterapii Centrum Onkologii
w Krakowie napromieniano pooperacyjnie 76 doros∏ych chorych na oponiaki Êródczaszkowe. Stosowano klasyczne techniki
i frakcjonacj´, dawka ca∏kowita na guz waha∏a si´ od 50 do 60 Gy (mediana 51 Gy).
W y n i k i.  Przy bardzo dobrej tolerancji leczenia 10-letnie aktualizowane prze˝ycie ca∏kowite wynios∏o 69%. W grupie 40
chorych na oponiaki ∏agodne odsetek 10-letnich aktualizowanych prze˝yç ca∏kowitych wyniós∏ 77% w porównaniu do 50%
dla chorych z oponiakiem z∏oÊliwym. Ró˝nica w prze˝yciach by∏a statystycznie znamienna (p=0,0125). W analizie
jednowariantowej nie wykazano wartoÊci rokowniczej wieku i p∏ci chorych, umiejscowienia guza oraz stopnia doszcz´tnoÊci
zabiegu operacyjnego.
W n i o s e k.  Klasycznie frakcjonowane pooperacyjne napromienianie chorych na oponiaki Êródczaszkowe jest bezpiecznà
i skutecznà metodà leczenia.
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There were 40 cases of benign and 36 of malignant
meningiomas (according to the WHO classification). Patient
characteristics according to histology are shown in Table I.
Table I. Patients characteristics
Characteristics Benign Malignant
meningioma meningioma
Age (years)
50 and less 10 11
More than 50 30 25
Gender
Female 21 20
Male 19 16
Tumor location
Convexity 11 15
Falx, parasagital 11 8
Other 18 13
Surgery
Partial resection 38 27
Total resection 2 9
Radiotherapy started 4 to 10 weeks after surgery and was
given with a Cobalt-60 unit.
Whole brain irradiation (19 cases of malignant meningioma
treated between 1975 and1984) was delivered by the means of
two opposed lateral fields. The tumor dose of 50 Gy in 25
fractions in 5 weeks was calculated on the central axis of the
treatment fields at the midplane of the skull. The treatment
fields were then reduced to cover the known tumor-bearing
area plus 2-3 cm of surrounding healthy brain tissue, and a 10 Gy
"boost" was given in 5 fractions over 5 days. From 1985, the
treatment volume covered the tumor residual with a margin of 2-
3 cm, and a dose of 60 Gy in 30 fractions was given over 6 weeks.
S u p p o r t i v e  t r e a t m e n t
Systemic anticonvulsants (Phenytoine or Phenobarbital) were
administered to all patients during irradiation. Dexamethasone
(12-20 mg/day) was given only as symptomatic medication
required to control cerebral edema.
S t a t i s t i c a l  c o n s i d e r a t i o n s
The cause-specific failure was unknown in a large proportion of
patients (60%), and for this reason the overall survival was
determined as the endpoint in the present series. Survival plots
were generated using the Kaplan-Meier method, and then data
was analyzed using the Gehan modification of the Wilcoxon
rank-sum analysis for comparing arbitrarily censored samples [6,
7].
Results
The treatment was generally well tolerated. During
radiotherapy, 14 patients (18%) showed improvement in
neurological function, in 62 cases neurological deficits
were assessed as steady. The 10-year actuarial overall
survival in the entire group of 76 patients was 69%
(Figure 1). The Kaplan-Meier survival curves according to
histology are presented in Figure 2.
The 10-year actuarial overall survival for patients
with benign and malignant variants of meningioma was
77% and 50%, respectively (two-tailed Gehan P-value =
0.0125).
The age and gender of patients, tumor location and
the extent of surgery was not a prognostic factor for
survival.
Discussion and conclusions
Our observations of clinical population features of adult
patients with intracranial meningiomas are similar to
those reported by other authors. The majority of patients
were in the fifth and sixth decade of age, and the most
common site of tumor is brain convexity [1, 2, 8]. The
high ratio (47%) of malignant forms is interesting. In this
respect, our group resembles the series from the Maria
Sk∏odowska-Curie Memorial Cancer Center in Warsaw,
where the reported ratio of malignant tumors was 43%
[9]. It suggests a similar selection of patients resulting
from similar indications for adjuvant irradiation in
meningioma patients. In other reports, malignant
meningiomas do not exceed 25% [10-12].
In the present series 5- and 10-year actuarial overall
survival rates were 80% and 69%, respectively. Our
results are comparable with observations of Bataini from
Institute Curie (Paris) [13]. An interesting study from
another French center (CHU Bordeaux) of 91 menin-
gioma patients treated with radiotherapy was reported
Figure 1. Actuarial overall survival of 76 patients
Figure 2. Actuarial overall survival according to the histology
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by Maire et al. Contemporary techniques were used,
a median dose of 52 Gy was given and the 5- and 10-year
survival rates were 71% and 40%, respectively [14].
Univariate analysis of our results demonstrates that
malignant histology is an important adverse prognostic
factor for survival. All published reports have shown poor
treatment outcomes in patients with malignant (ana-
plastic) meningioma. These tumors widely infiltrate
adjacent tissues, and recur early following even "complete"
surgical excision and after adequate contemporary
radiotherapy [10, 13, 15]. These observations are con-
firmed by the National Cancer Data Base (NCDB)
report, covering the population of over 9000 patients with
meningioma treated in USA in the years 1985 – 1992.
The overall 10-year survival rates for patients with benign
and malignant meningioma were 70% and 51%,
respectively [16]. An important study was published by
Milosevic from the Princess Margaret Hospital (Toronto)
covering the treatment outcomes in 59 patients, including
42 (71%) with malignant and 17 with atypical menin-
gioma. The 5-year actuarial overall and disease-specific
survival (DSS) was 28% and 34%, respectively. In
multivariate analysis, age below 58 years and a radiation
dose higher than 50 Gy were independent prognostic
factors associated with higher DSS [17].
In this analysis, patient age was found not to be
a prognostic factor for survival, contrary to other authors.
The K´pka et al. series, with pathoclinical characteristics
resembling our material, age over 50 years had a negative
effect on prognosis [9]. Authors from the NCDB have
also confirmed the role of age in the outcome of patients
with meningioma. The actuarial 10-year survival rates
were 50% and 81%, respectively for patients at ages
above and below 60 years of age [16]. Similar observations
were reported by Goldsmith and Leibel [10, 18].
We found no relationship between tumor location
and patient outcome, nevertheless one should mention
the opinion of Ayerbe et al. on the adverse influence on
prognosis in case of tumors located on the cerebral
convexity [2, 13, 15, 16].
In the present study, the extent of surgery (total vs
partial resection) did not result in significant differences
in survival. The prognostic value of this therapeutic factor
is a point of controversial reports in the literature,
probably resulting from subjective assessments of
resection. K´pka et al. compare the results obtained in
two groups: patients with total tumor removal vs. patients
with subtotal, partial resections or biopsies. 5-year survival
rates were 75% and 54%, respectively (p=0.06). Separate
assessment of results according to tumor histology (benign
vs, anaplastic) results in pronouncing the extent of surgery
to be not of prognostic value [9].
Primary treatment in the management of menin-
gioma is surgery, with radiotherapy as an important
postoperative measure in selected patients with malignant
histology, or after incomplete resection. Salazar has
combined several studies and found a 58% recurrence
rate following gross total resection and a 90% recurrence
rate following subtotal resection of malignant menin-
giomas, which fell to 36% and 41%, respectively when
surgery was followed by external beam irradiation [19].
Barbaro et al. has shown, that 60% of no irradiated
patients suffered recurrence, as compared to 32% of
those who had received radiation therapy [8]. Taylor
found an incidence of recurrence of 49% in patients
receiving postoperative irradiation vs 81% when no
radiotherapy was performed after subtotal resection [12].
Mirabell et al. have presented similar findings [20]. An
interesting study on malignant meningioma was published
by the Bayor College of Medicine in Houston. The 5-
year actuarial disease-free survival was 39% in patients
with complete resection, whereas none of the patients
after incomplete resection survived five years. Post-
operative radiotherapy as a planned part of the initial
treatment increased the 5-year survival from 15% to 80%
(p=0.002) [21].
Our results compare favorably with previously
published reports. External fractionated radiotherapy is
well tolerated, the recommended radiation dose and
target volume average at least 60 Gy with the 2-3 cm
margin. The effectiveness of higher radiation doses must
be weighted against possible complications, especially in
patients with benign meningioma, because of the long
survival of patients and a potential risk of radio-necrosis.
Based on the published data and the experience at
our Institution we suggest that patients with malignant
meningiomas should undergo postoperative irradiation.
The role of radiotherapy in the treatment of benign
meningiomas after subtotal resection is still debated,
should irradiation be given postoperatively or at the time
of progression? Prospective randomized multicenter trials
would be required to clear these issues.
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